Takeda Reports Zasocitinib Achieves Rapid Skin Clearance

Takeda today announced Phase 3 results for zasocitinib (TAK-279), presented as a late-breaking abstract at the 2026 AAD Annual Meeting, showing rapid, durable skin clearance in adults with moderate-to-severe plaque psoriasis. About 70% of patients achieved clear or almost clear skin (sPGA 0/1) at week 16 versus 10–13% for placebo, with a safety profile consistent with Phase 2b findings.